| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H11N3O4 |
| Molecular Weight | 213.1906 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(=O)N(C=C1)[C@@H]2CO[C@H](CO)O2
InChI
InChIKey=RXRGZNYSEHTMHC-BQBZGAKWSA-N
InChI=1S/C8H11N3O4/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7-/m0/s1
| Molecular Formula | C8H11N3O4 |
| Molecular Weight | 213.1906 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Troxacitabine is a synthetic nucleoside analogue. It is a poor substrate for nucleoside transporters and gains entry into cells by passive diffusion. Intracellular conversion to its active triphosphate form is via deoxycytidine kinase. Incorporation of this metabolite into DNA results in immediate chain termination and apoptosis induction. It is the first nucleoside analog with anticancer activity that has an unnatural stereochemical configuration. The dose-limiting adverse reactions were stomatitis and hand–foot syndrome.
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
The recommended dose was defined as 8mg/m2/day over 30 minutes for 5 days.
Route of Administration:
Intravenous
|
|
METABOLITE ACTIVE -> PRODRUG |
|
Showing 1 to 1 of 1 entries
